nodes	percent_of_prediction	percent_of_DWPC	metapath
Ergotamine—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0491	0.0706	CbGbCtD
Ergotamine—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0462	0.0664	CbGbCtD
Ergotamine—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0462	0.0664	CbGbCtD
Ergotamine—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.0418	0.06	CbGbCtD
Ergotamine—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0404	0.0581	CbGbCtD
Ergotamine—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0365	0.0525	CbGbCtD
Ergotamine—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.035	0.0503	CbGbCtD
Ergotamine—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.0317	0.0455	CbGbCtD
Ergotamine—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0315	0.0453	CbGbCtD
Ergotamine—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.0306	0.044	CbGbCtD
Ergotamine—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0277	0.0398	CbGbCtD
Ergotamine—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0277	0.0398	CbGbCtD
Ergotamine—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.0265	0.0382	CbGbCtD
Ergotamine—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0257	0.037	CbGbCtD
Ergotamine—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0242	0.0348	CbGbCtD
Ergotamine—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0242	0.0348	CbGbCtD
Ergotamine—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0219	0.0315	CbGbCtD
Ergotamine—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0219	0.0315	CbGbCtD
Ergotamine—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.0205	0.0295	CbGbCtD
Ergotamine—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0189	0.0272	CbGbCtD
Ergotamine—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0183	0.0264	CbGbCtD
Ergotamine—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.0166	0.0238	CbGbCtD
Ergotamine—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.0166	0.0238	CbGbCtD
Ergotamine—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0159	0.0229	CbGbCtD
Ergotamine—Localised oedema—Zidovudine—acquired immunodeficiency syndrome	0.011	0.0705	CcSEcCtD
Ergotamine—Localised oedema—Lamivudine—acquired immunodeficiency syndrome	0.00783	0.0503	CcSEcCtD
Ergotamine—Ischaemia—Ritonavir—acquired immunodeficiency syndrome	0.00591	0.0379	CcSEcCtD
Ergotamine—Peripheral coldness—Ritonavir—acquired immunodeficiency syndrome	0.00453	0.0291	CcSEcCtD
Ergotamine—Numbness—Didanosine—acquired immunodeficiency syndrome	0.00443	0.0285	CcSEcCtD
Ergotamine—Sensory loss—Didanosine—acquired immunodeficiency syndrome	0.00424	0.0272	CcSEcCtD
Ergotamine—Numbness—Stavudine—acquired immunodeficiency syndrome	0.00385	0.0247	CcSEcCtD
Ergotamine—Sensory loss—Stavudine—acquired immunodeficiency syndrome	0.00368	0.0236	CcSEcCtD
Ergotamine—Cyanosis—Saquinavir—acquired immunodeficiency syndrome	0.00293	0.0188	CcSEcCtD
Ergotamine—SLC6A2—nerve—acquired immunodeficiency syndrome	0.0026	0.0381	CbGeAlD
Ergotamine—DRD2—nerve—acquired immunodeficiency syndrome	0.00236	0.0347	CbGeAlD
Ergotamine—HTR1A—blood plasma—acquired immunodeficiency syndrome	0.00198	0.0291	CbGeAlD
Ergotamine—Hypoaesthesia—Didanosine—acquired immunodeficiency syndrome	0.00184	0.0118	CcSEcCtD
Ergotamine—HTR1F—nervous system—acquired immunodeficiency syndrome	0.00178	0.0261	CbGeAlD
Ergotamine—HTR1F—central nervous system—acquired immunodeficiency syndrome	0.00171	0.0252	CbGeAlD
Ergotamine—Hypoaesthesia—Stavudine—acquired immunodeficiency syndrome	0.00159	0.0102	CcSEcCtD
Ergotamine—HTR2A—nerve—acquired immunodeficiency syndrome	0.00156	0.0229	CbGeAlD
Ergotamine—HTR1E—nervous system—acquired immunodeficiency syndrome	0.00154	0.0226	CbGeAlD
Ergotamine—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.00151	0.0222	CbGeAlD
Ergotamine—Myalgia—Amprenavir—acquired immunodeficiency syndrome	0.0015	0.00963	CcSEcCtD
Ergotamine—HTR1E—central nervous system—acquired immunodeficiency syndrome	0.00148	0.0218	CbGeAlD
Ergotamine—ADRA2A—blood plasma—acquired immunodeficiency syndrome	0.00139	0.0204	CbGeAlD
Ergotamine—Myalgia—Didanosine—acquired immunodeficiency syndrome	0.00137	0.00878	CcSEcCtD
Ergotamine—HTR1F—brain—acquired immunodeficiency syndrome	0.00136	0.02	CbGeAlD
Ergotamine—HTR2A—endothelium—acquired immunodeficiency syndrome	0.00133	0.0195	CbGeAlD
Ergotamine—Musculoskeletal discomfort—Amprenavir—acquired immunodeficiency syndrome	0.00131	0.00841	CcSEcCtD
Ergotamine—Paraesthesia—Amprenavir—acquired immunodeficiency syndrome	0.00129	0.00829	CcSEcCtD
Ergotamine—Hypoaesthesia—Indinavir—acquired immunodeficiency syndrome	0.00129	0.00827	CcSEcCtD
Ergotamine—Vertigo—Abacavir—acquired immunodeficiency syndrome	0.00123	0.00793	CcSEcCtD
Ergotamine—Myalgia—Nevirapine—acquired immunodeficiency syndrome	0.00123	0.0079	CcSEcCtD
Ergotamine—Hypoaesthesia—Efavirenz—acquired immunodeficiency syndrome	0.00122	0.00782	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Didanosine—acquired immunodeficiency syndrome	0.00119	0.00767	CcSEcCtD
Ergotamine—Bradycardia—Delavirdine—acquired immunodeficiency syndrome	0.00119	0.00765	CcSEcCtD
Ergotamine—Myalgia—Nelfinavir—acquired immunodeficiency syndrome	0.00119	0.00765	CcSEcCtD
Ergotamine—Myalgia—Stavudine—acquired immunodeficiency syndrome	0.00119	0.00762	CcSEcCtD
Ergotamine—HTR2A—blood plasma—acquired immunodeficiency syndrome	0.00118	0.0173	CbGeAlD
Ergotamine—HTR1E—brain—acquired immunodeficiency syndrome	0.00118	0.0173	CbGeAlD
Ergotamine—Paraesthesia—Didanosine—acquired immunodeficiency syndrome	0.00118	0.00756	CcSEcCtD
Ergotamine—Myalgia—Abacavir—acquired immunodeficiency syndrome	0.00117	0.00751	CcSEcCtD
Ergotamine—Hypoaesthesia—Delavirdine—acquired immunodeficiency syndrome	0.00116	0.00748	CcSEcCtD
Ergotamine—Pain—Didanosine—acquired immunodeficiency syndrome	0.00112	0.0072	CcSEcCtD
Ergotamine—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.00109	0.016	CbGeAlD
Ergotamine—Vertigo—Zidovudine—acquired immunodeficiency syndrome	0.00109	0.00699	CcSEcCtD
Ergotamine—Hypoaesthesia—Ritonavir—acquired immunodeficiency syndrome	0.00108	0.00692	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Nevirapine—acquired immunodeficiency syndrome	0.00107	0.0069	CcSEcCtD
Ergotamine—HTR2B—skin of body—acquired immunodeficiency syndrome	0.00106	0.0156	CbGeAlD
Ergotamine—Paraesthesia—Nevirapine—acquired immunodeficiency syndrome	0.00106	0.0068	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Nelfinavir—acquired immunodeficiency syndrome	0.00104	0.00668	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Stavudine—acquired immunodeficiency syndrome	0.00104	0.00666	CcSEcCtD
Ergotamine—Hypoaesthesia—Saquinavir—acquired immunodeficiency syndrome	0.00104	0.00666	CcSEcCtD
Ergotamine—Myalgia—Zidovudine—acquired immunodeficiency syndrome	0.00103	0.00663	CcSEcCtD
Ergotamine—Asthenia—Amprenavir—acquired immunodeficiency syndrome	0.00103	0.00663	CcSEcCtD
Ergotamine—Paraesthesia—Nelfinavir—acquired immunodeficiency syndrome	0.00102	0.00658	CcSEcCtD
Ergotamine—Paraesthesia—Stavudine—acquired immunodeficiency syndrome	0.00102	0.00656	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Abacavir—acquired immunodeficiency syndrome	0.00102	0.00656	CcSEcCtD
Ergotamine—Pruritus—Amprenavir—acquired immunodeficiency syndrome	0.00102	0.00653	CcSEcCtD
Ergotamine—Vertigo—Indinavir—acquired immunodeficiency syndrome	0.00101	0.0065	CcSEcCtD
Ergotamine—Pain—Nevirapine—acquired immunodeficiency syndrome	0.00101	0.00647	CcSEcCtD
Ergotamine—Paraesthesia—Abacavir—acquired immunodeficiency syndrome	0.00101	0.00647	CcSEcCtD
Ergotamine—Hypoaesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000989	0.00635	CcSEcCtD
Ergotamine—DRD2—retina—acquired immunodeficiency syndrome	0.000979	0.0144	CbGeAlD
Ergotamine—Pain—Nelfinavir—acquired immunodeficiency syndrome	0.000976	0.00627	CcSEcCtD
Ergotamine—Pain—Stavudine—acquired immunodeficiency syndrome	0.000973	0.00625	CcSEcCtD
Ergotamine—ADRA1B—nervous system—acquired immunodeficiency syndrome	0.000966	0.0142	CbGeAlD
Ergotamine—Myalgia—Indinavir—acquired immunodeficiency syndrome	0.000959	0.00616	CcSEcCtD
Ergotamine—Pain—Abacavir—acquired immunodeficiency syndrome	0.000958	0.00616	CcSEcCtD
Ergotamine—Vertigo—Efavirenz—acquired immunodeficiency syndrome	0.000957	0.00615	CcSEcCtD
Ergotamine—ADRA1D—nervous system—acquired immunodeficiency syndrome	0.000945	0.0139	CbGeAlD
Ergotamine—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.00094	0.00604	CcSEcCtD
Ergotamine—ADRA1B—central nervous system—acquired immunodeficiency syndrome	0.00093	0.0137	CbGeAlD
Ergotamine—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.000927	0.00596	CcSEcCtD
Ergotamine—Hypertension—Efavirenz—acquired immunodeficiency syndrome	0.000919	0.00591	CcSEcCtD
Ergotamine—Vertigo—Delavirdine—acquired immunodeficiency syndrome	0.000915	0.00588	CcSEcCtD
Ergotamine—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.000914	0.00587	CcSEcCtD
Ergotamine—ADRA1D—central nervous system—acquired immunodeficiency syndrome	0.00091	0.0134	CbGeAlD
Ergotamine—Myalgia—Efavirenz—acquired immunodeficiency syndrome	0.000906	0.00582	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Zidovudine—acquired immunodeficiency syndrome	0.000901	0.00579	CcSEcCtD
Ergotamine—Paraesthesia—Zidovudine—acquired immunodeficiency syndrome	0.000888	0.0057	CcSEcCtD
Ergotamine—Hypertension—Delavirdine—acquired immunodeficiency syndrome	0.00088	0.00565	CcSEcCtD
Ergotamine—Myalgia—Delavirdine—acquired immunodeficiency syndrome	0.000867	0.00557	CcSEcCtD
Ergotamine—HTR1B—spinal cord—acquired immunodeficiency syndrome	0.000866	0.0127	CbGeAlD
Ergotamine—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000854	0.00549	CcSEcCtD
Ergotamine—HTR2B—digestive system—acquired immunodeficiency syndrome	0.000849	0.0125	CbGeAlD
Ergotamine—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.000848	0.00545	CcSEcCtD
Ergotamine—Vertigo—Ritonavir—acquired immunodeficiency syndrome	0.000846	0.00544	CcSEcCtD
Ergotamine—Pain—Zidovudine—acquired immunodeficiency syndrome	0.000846	0.00543	CcSEcCtD
Ergotamine—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000845	0.00543	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	0.000838	0.00538	CcSEcCtD
Ergotamine—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000834	0.00536	CcSEcCtD
Ergotamine—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000833	0.00535	CcSEcCtD
Ergotamine—HTR2C—spinal cord—acquired immunodeficiency syndrome	0.00083	0.0122	CbGeAlD
Ergotamine—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.000826	0.00531	CcSEcCtD
Ergotamine—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000819	0.00526	CcSEcCtD
Ergotamine—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000816	0.00524	CcSEcCtD
Ergotamine—Vertigo—Saquinavir—acquired immunodeficiency syndrome	0.000815	0.00523	CcSEcCtD
Ergotamine—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000813	0.00523	CcSEcCtD
Ergotamine—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000811	0.00521	CcSEcCtD
Ergotamine—HTR2B—blood—acquired immunodeficiency syndrome	0.000809	0.0119	CbGeAlD
Ergotamine—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000807	0.00519	CcSEcCtD
Ergotamine—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000805	0.00517	CcSEcCtD
Ergotamine—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000804	0.00517	CcSEcCtD
Ergotamine—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.000802	0.00515	CcSEcCtD
Ergotamine—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000793	0.00509	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000792	0.00509	CcSEcCtD
Ergotamine—Pain—Indinavir—acquired immunodeficiency syndrome	0.000786	0.00505	CcSEcCtD
Ergotamine—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000783	0.00503	CcSEcCtD
Ergotamine—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.00078	0.00501	CcSEcCtD
Ergotamine—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000778	0.005	CcSEcCtD
Ergotamine—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000777	0.00499	CcSEcCtD
Ergotamine—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000773	0.0114	CbGeAlD
Ergotamine—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.000772	0.00496	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000757	0.00487	CcSEcCtD
Ergotamine—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.00075	0.00482	CcSEcCtD
Ergotamine—HTR2B—vagina—acquired immunodeficiency syndrome	0.00075	0.011	CbGeAlD
Ergotamine—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000749	0.00481	CcSEcCtD
Ergotamine—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000747	0.0048	CcSEcCtD
Ergotamine—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000743	0.00477	CcSEcCtD
Ergotamine—ADRA1B—brain—acquired immunodeficiency syndrome	0.000738	0.0108	CbGeAlD
Ergotamine—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.000736	0.00473	CcSEcCtD
Ergotamine—HTR1B—nervous system—acquired immunodeficiency syndrome	0.000729	0.0107	CbGeAlD
Ergotamine—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000726	0.00466	CcSEcCtD
Ergotamine—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000723	0.00465	CcSEcCtD
Ergotamine—ADRA1D—brain—acquired immunodeficiency syndrome	0.000722	0.0106	CbGeAlD
Ergotamine—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000713	0.00458	CcSEcCtD
Ergotamine—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000711	0.00457	CcSEcCtD
Ergotamine—ADRA1A—lymphoid tissue—acquired immunodeficiency syndrome	0.00071	0.0104	CbGeAlD
Ergotamine—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.00071	0.00456	CcSEcCtD
Ergotamine—HTR2B—lung—acquired immunodeficiency syndrome	0.000709	0.0104	CbGeAlD
Ergotamine—HTR1D—nervous system—acquired immunodeficiency syndrome	0.000706	0.0104	CbGeAlD
Ergotamine—HTR1B—central nervous system—acquired immunodeficiency syndrome	0.000702	0.0103	CbGeAlD
Ergotamine—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.0007	0.0045	CcSEcCtD
Ergotamine—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.0007	0.0045	CcSEcCtD
Ergotamine—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.0007	0.00449	CcSEcCtD
Ergotamine—HTR2C—nervous system—acquired immunodeficiency syndrome	0.000699	0.0103	CbGeAlD
Ergotamine—HTR1A—spinal cord—acquired immunodeficiency syndrome	0.000699	0.0103	CbGeAlD
Ergotamine—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.00069	0.00444	CcSEcCtD
Ergotamine—HTR1D—central nervous system—acquired immunodeficiency syndrome	0.00068	0.00998	CbGeAlD
Ergotamine—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000678	0.00435	CcSEcCtD
Ergotamine—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000676	0.00434	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000674	0.00433	CcSEcCtD
Ergotamine—HTR2C—central nervous system—acquired immunodeficiency syndrome	0.000673	0.00989	CbGeAlD
Ergotamine—ADRA1A—blood—acquired immunodeficiency syndrome	0.000668	0.00982	CbGeAlD
Ergotamine—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000666	0.00428	CcSEcCtD
Ergotamine—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.000664	0.00427	CcSEcCtD
Ergotamine—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.00066	0.00424	CcSEcCtD
Ergotamine—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000657	0.00422	CcSEcCtD
Ergotamine—HTR2B—nervous system—acquired immunodeficiency syndrome	0.000657	0.00965	CbGeAlD
Ergotamine—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000651	0.00418	CcSEcCtD
Ergotamine—HTR2A—retina—acquired immunodeficiency syndrome	0.000646	0.00949	CbGeAlD
Ergotamine—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000643	0.00413	CcSEcCtD
Ergotamine—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000634	0.00407	CcSEcCtD
Ergotamine—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000633	0.00407	CcSEcCtD
Ergotamine—HTR2B—central nervous system—acquired immunodeficiency syndrome	0.000633	0.00929	CbGeAlD
Ergotamine—SLC6A2—lung—acquired immunodeficiency syndrome	0.00063	0.00926	CbGeAlD
Ergotamine—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000629	0.00404	CcSEcCtD
Ergotamine—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000623	0.00401	CcSEcCtD
Ergotamine—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000615	0.00395	CcSEcCtD
Ergotamine—Pain—Lamivudine—acquired immunodeficiency syndrome	0.000604	0.00388	CcSEcCtD
Ergotamine—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000597	0.00383	CcSEcCtD
Ergotamine—HTR1A—nervous system—acquired immunodeficiency syndrome	0.000589	0.00864	CbGeAlD
Ergotamine—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000588	0.00378	CcSEcCtD
Ergotamine—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000587	0.00377	CcSEcCtD
Ergotamine—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000585	0.00376	CcSEcCtD
Ergotamine—SLC6A2—nervous system—acquired immunodeficiency syndrome	0.000584	0.00857	CbGeAlD
Ergotamine—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.00058	0.00852	CbGeAlD
Ergotamine—DRD2—lung—acquired immunodeficiency syndrome	0.000574	0.00843	CbGeAlD
Ergotamine—HTR1A—central nervous system—acquired immunodeficiency syndrome	0.000567	0.00832	CbGeAlD
Ergotamine—SLC6A2—central nervous system—acquired immunodeficiency syndrome	0.000562	0.00825	CbGeAlD
Ergotamine—HTR1B—brain—acquired immunodeficiency syndrome	0.000558	0.00819	CbGeAlD
Ergotamine—CYP1A2—blood—acquired immunodeficiency syndrome	0.000553	0.00812	CbGeAlD
Ergotamine—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000552	0.00355	CcSEcCtD
Ergotamine—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000552	0.00354	CcSEcCtD
Ergotamine—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000546	0.00351	CcSEcCtD
Ergotamine—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000544	0.00349	CcSEcCtD
Ergotamine—ADRA1A—nervous system—acquired immunodeficiency syndrome	0.000543	0.00797	CbGeAlD
Ergotamine—HTR1D—brain—acquired immunodeficiency syndrome	0.00054	0.00793	CbGeAlD
Ergotamine—HTR2C—brain—acquired immunodeficiency syndrome	0.000535	0.00785	CbGeAlD
Ergotamine—DRD2—nervous system—acquired immunodeficiency syndrome	0.000532	0.00781	CbGeAlD
Ergotamine—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000531	0.00341	CcSEcCtD
Ergotamine—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000529	0.0034	CcSEcCtD
Ergotamine—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000524	0.00336	CcSEcCtD
Ergotamine—ADRA1A—central nervous system—acquired immunodeficiency syndrome	0.000522	0.00767	CbGeAlD
Ergotamine—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000516	0.00332	CcSEcCtD
Ergotamine—DRD2—central nervous system—acquired immunodeficiency syndrome	0.000512	0.00752	CbGeAlD
Ergotamine—ADRA2A—blood—acquired immunodeficiency syndrome	0.000508	0.00746	CbGeAlD
Ergotamine—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000506	0.00325	CcSEcCtD
Ergotamine—HTR2B—brain—acquired immunodeficiency syndrome	0.000502	0.00737	CbGeAlD
Ergotamine—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000499	0.00321	CcSEcCtD
Ergotamine—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000494	0.00317	CcSEcCtD
Ergotamine—ADRA2A—spinal cord—acquired immunodeficiency syndrome	0.00049	0.00719	CbGeAlD
Ergotamine—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000489	0.00314	CcSEcCtD
Ergotamine—HTR2B—lymph node—acquired immunodeficiency syndrome	0.000485	0.00712	CbGeAlD
Ergotamine—CYP1A2—lung—acquired immunodeficiency syndrome	0.000485	0.00711	CbGeAlD
Ergotamine—ADRA2A—vagina—acquired immunodeficiency syndrome	0.000471	0.00692	CbGeAlD
Ergotamine—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.00047	0.00302	CcSEcCtD
Ergotamine—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000457	0.00293	CcSEcCtD
Ergotamine—HTR2A—digestive system—acquired immunodeficiency syndrome	0.000454	0.00666	CbGeAlD
Ergotamine—HTR1A—brain—acquired immunodeficiency syndrome	0.00045	0.00661	CbGeAlD
Ergotamine—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000449	0.00288	CcSEcCtD
Ergotamine—SLC6A2—brain—acquired immunodeficiency syndrome	0.000446	0.00655	CbGeAlD
Ergotamine—ADRA2A—lung—acquired immunodeficiency syndrome	0.000446	0.00654	CbGeAlD
Ergotamine—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.00044	0.00282	CcSEcCtD
Ergotamine—HTR2A—blood—acquired immunodeficiency syndrome	0.000432	0.00635	CbGeAlD
Ergotamine—SLC6A2—lymph node—acquired immunodeficiency syndrome	0.000431	0.00633	CbGeAlD
Ergotamine—ABCB1—retina—acquired immunodeficiency syndrome	0.000423	0.00622	CbGeAlD
Ergotamine—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.00042	0.00617	CbGeAlD
Ergotamine—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000419	0.00269	CcSEcCtD
Ergotamine—HTR2A—spinal cord—acquired immunodeficiency syndrome	0.000416	0.00611	CbGeAlD
Ergotamine—ADRA1A—brain—acquired immunodeficiency syndrome	0.000415	0.00609	CbGeAlD
Ergotamine—ADRA2A—nervous system—acquired immunodeficiency syndrome	0.000413	0.00606	CbGeAlD
Ergotamine—DRD2—brain—acquired immunodeficiency syndrome	0.000407	0.00597	CbGeAlD
Ergotamine—HTR2A—vagina—acquired immunodeficiency syndrome	0.000401	0.00588	CbGeAlD
Ergotamine—CYP3A4—blood—acquired immunodeficiency syndrome	0.0004	0.00587	CbGeAlD
Ergotamine—ADRA2A—central nervous system—acquired immunodeficiency syndrome	0.000397	0.00583	CbGeAlD
Ergotamine—HTR2A—lung—acquired immunodeficiency syndrome	0.000379	0.00556	CbGeAlD
Ergotamine—HTR2A—nervous system—acquired immunodeficiency syndrome	0.000351	0.00515	CbGeAlD
Ergotamine—HTR2A—central nervous system—acquired immunodeficiency syndrome	0.000338	0.00496	CbGeAlD
Ergotamine—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000325	0.00477	CbGeAlD
Ergotamine—ADRA2A—brain—acquired immunodeficiency syndrome	0.000315	0.00463	CbGeAlD
Ergotamine—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000313	0.00459	CbGeAlD
Ergotamine—ADRA2A—lymph node—acquired immunodeficiency syndrome	0.000305	0.00447	CbGeAlD
Ergotamine—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000301	0.00442	CbGeAlD
Ergotamine—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000297	0.00436	CbGeAlD
Ergotamine—ABCB1—blood—acquired immunodeficiency syndrome	0.000283	0.00416	CbGeAlD
Ergotamine—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000274	0.00402	CbGeAlD
Ergotamine—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000273	0.00401	CbGeAlD
Ergotamine—HTR2A—brain—acquired immunodeficiency syndrome	0.000268	0.00394	CbGeAlD
Ergotamine—ABCB1—vagina—acquired immunodeficiency syndrome	0.000263	0.00385	CbGeAlD
Ergotamine—ABCB1—lung—acquired immunodeficiency syndrome	0.000248	0.00365	CbGeAlD
Ergotamine—ABCB1—nervous system—acquired immunodeficiency syndrome	0.00023	0.00338	CbGeAlD
Ergotamine—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000221	0.00325	CbGeAlD
Ergotamine—ABCB1—brain—acquired immunodeficiency syndrome	0.000176	0.00258	CbGeAlD
Ergotamine—ABCB1—lymph node—acquired immunodeficiency syndrome	0.00017	0.00249	CbGeAlD
Ergotamine—HTR1B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.92e-05	0.000487	CbGpPWpGaD
Ergotamine—SLC6A2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	3.91e-05	0.000485	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.87e-05	0.00048	CbGpPWpGaD
Ergotamine—HTR1B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.87e-05	0.00048	CbGpPWpGaD
Ergotamine—HTR2A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	3.87e-05	0.00048	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.84e-05	0.000477	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.82e-05	0.000474	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.8e-05	0.000472	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.8e-05	0.000472	CbGpPWpGaD
Ergotamine—ADRA2B—Hemostasis—ALB—acquired immunodeficiency syndrome	3.79e-05	0.000471	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.78e-05	0.000469	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.78e-05	0.000469	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.78e-05	0.000469	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.77e-05	0.000467	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.76e-05	0.000466	CbGpPWpGaD
Ergotamine—ADRA2B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.73e-05	0.000463	CbGpPWpGaD
Ergotamine—ADRA1D—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.73e-05	0.000462	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.72e-05	0.000462	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.72e-05	0.000462	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.72e-05	0.000461	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.72e-05	0.000461	CbGpPWpGaD
Ergotamine—HTR1E—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.71e-05	0.00046	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.7e-05	0.000459	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.7e-05	0.000459	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	3.69e-05	0.000458	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.69e-05	0.000457	CbGpPWpGaD
Ergotamine—ADRA2B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.68e-05	0.000456	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.65e-05	0.000453	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.64e-05	0.000452	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.64e-05	0.000452	CbGpPWpGaD
Ergotamine—HTR2B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.64e-05	0.000451	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.63e-05	0.00045	CbGpPWpGaD
Ergotamine—HTR1A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.61e-05	0.000447	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.6e-05	0.000446	CbGpPWpGaD
Ergotamine—HTR2C—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.59e-05	0.000445	CbGpPWpGaD
Ergotamine—HTR1F—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.57e-05	0.000443	CbGpPWpGaD
Ergotamine—HTR1A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.55e-05	0.000441	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.55e-05	0.00044	CbGpPWpGaD
Ergotamine—HTR2C—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.53e-05	0.000438	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.45e-05	0.000427	CbGpPWpGaD
Ergotamine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	3.44e-05	0.000427	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.44e-05	0.000427	CbGpPWpGaD
Ergotamine—ADRA1B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.43e-05	0.000426	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.43e-05	0.000426	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.41e-05	0.000423	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.41e-05	0.000423	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.39e-05	0.000421	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.38e-05	0.00042	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.38e-05	0.00042	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.38e-05	0.00042	CbGpPWpGaD
Ergotamine—ADRA1B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.38e-05	0.00042	CbGpPWpGaD
Ergotamine—HTR1E—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.37e-05	0.000418	CbGpPWpGaD
Ergotamine—ADRA2B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.36e-05	0.000417	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.34e-05	0.000414	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.34e-05	0.000414	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.34e-05	0.000414	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.33e-05	0.000414	CbGpPWpGaD
Ergotamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	3.3e-05	0.000409	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.27e-05	0.000406	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.26e-05	0.000404	CbGpPWpGaD
Ergotamine—HTR1A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.25e-05	0.000403	CbGpPWpGaD
Ergotamine—HTR2C—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.23e-05	0.000401	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.23e-05	0.0004	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.21e-05	0.000398	CbGpPWpGaD
Ergotamine—DRD2—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	3.21e-05	0.000398	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.17e-05	0.000393	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	3.14e-05	0.00039	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.14e-05	0.000389	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.14e-05	0.000389	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.12e-05	0.000387	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.12e-05	0.000387	CbGpPWpGaD
Ergotamine—HTR2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.11e-05	0.000386	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.1e-05	0.000385	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.1e-05	0.000384	CbGpPWpGaD
Ergotamine—ADRA1B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.09e-05	0.000384	CbGpPWpGaD
Ergotamine—ADRA2B—Hemostasis—IL2—acquired immunodeficiency syndrome	3.08e-05	0.000382	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.07e-05	0.000381	CbGpPWpGaD
Ergotamine—HTR2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.07e-05	0.000381	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.06e-05	0.000379	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.05e-05	0.000378	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3e-05	0.000373	CbGpPWpGaD
Ergotamine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	2.99e-05	0.000371	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.99e-05	0.000371	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.97e-05	0.000369	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.95e-05	0.000366	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.93e-05	0.000364	CbGpPWpGaD
Ergotamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	2.93e-05	0.000363	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.92e-05	0.000362	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.92e-05	0.000362	CbGpPWpGaD
Ergotamine—ADRA2A—Hemostasis—ALB—acquired immunodeficiency syndrome	2.88e-05	0.000357	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.87e-05	0.000357	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.85e-05	0.000354	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	2.85e-05	0.000354	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.85e-05	0.000353	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.83e-05	0.000352	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.83e-05	0.000351	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.83e-05	0.000351	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.81e-05	0.000348	CbGpPWpGaD
Ergotamine—HTR2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.81e-05	0.000348	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.8e-05	0.000347	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.79e-05	0.000346	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.79e-05	0.000346	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.77e-05	0.000344	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.75e-05	0.000341	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.73e-05	0.000338	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.7e-05	0.000335	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.69e-05	0.000334	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.63e-05	0.000327	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.63e-05	0.000327	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.63e-05	0.000326	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.59e-05	0.000322	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.59e-05	0.000321	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.58e-05	0.00032	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.58e-05	0.000319	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.57e-05	0.000319	CbGpPWpGaD
Ergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	2.56e-05	0.000318	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.55e-05	0.000317	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.55e-05	0.000317	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.55e-05	0.000316	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.54e-05	0.000315	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.54e-05	0.000315	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.54e-05	0.000315	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.53e-05	0.000314	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.53e-05	0.000314	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.53e-05	0.000314	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.53e-05	0.000314	CbGpPWpGaD
Ergotamine—HTR1D—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.52e-05	0.000312	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.5e-05	0.00031	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.5e-05	0.00031	CbGpPWpGaD
Ergotamine—HTR1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.46e-05	0.000306	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	2.42e-05	0.000301	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.42e-05	0.0003	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.42e-05	0.0003	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.39e-05	0.000296	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.37e-05	0.000295	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.35e-05	0.000292	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.35e-05	0.000291	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.34e-05	0.00029	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.34e-05	0.00029	CbGpPWpGaD
Ergotamine—ADRA2A—Hemostasis—IL2—acquired immunodeficiency syndrome	2.33e-05	0.00029	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.32e-05	0.000288	CbGpPWpGaD
Ergotamine—HTR2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.31e-05	0.000287	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.29e-05	0.000284	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.29e-05	0.000284	CbGpPWpGaD
Ergotamine—HTR1D—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.28e-05	0.000283	CbGpPWpGaD
Ergotamine—HTR1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.24e-05	0.000278	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.23e-05	0.000277	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.23e-05	0.000277	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.22e-05	0.000275	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.2e-05	0.000272	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.2e-05	0.000272	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.19e-05	0.000271	CbGpPWpGaD
Ergotamine—ADRA1D—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.15e-05	0.000267	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.15e-05	0.000267	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.15e-05	0.000267	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.15e-05	0.000267	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.13e-05	0.000264	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.11e-05	0.000262	CbGpPWpGaD
Ergotamine—HTR2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.1e-05	0.000261	CbGpPWpGaD
Ergotamine—HTR1F—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.1e-05	0.000261	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2e-05	0.000249	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2e-05	0.000248	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2e-05	0.000248	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2e-05	0.000248	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.99e-05	0.000247	CbGpPWpGaD
Ergotamine—HTR1E—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.98e-05	0.000246	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.97e-05	0.000245	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.96e-05	0.000243	CbGpPWpGaD
Ergotamine—ADRA2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.94e-05	0.000241	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.93e-05	0.00024	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.92e-05	0.000239	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.91e-05	0.000236	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.9e-05	0.000235	CbGpPWpGaD
Ergotamine—HTR1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.88e-05	0.000233	CbGpPWpGaD
Ergotamine—HTR2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.87e-05	0.000232	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.84e-05	0.000228	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.81e-05	0.000225	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.81e-05	0.000224	CbGpPWpGaD
Ergotamine—ADRA1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.79e-05	0.000222	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.77e-05	0.000219	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.74e-05	0.000216	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.73e-05	0.000215	CbGpPWpGaD
Ergotamine—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.72e-05	0.000214	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.7e-05	0.000211	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.7e-05	0.000211	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.7e-05	0.00021	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.67e-05	0.000207	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.67e-05	0.000207	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.66e-05	0.000206	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.65e-05	0.000204	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.65e-05	0.000204	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.64e-05	0.000203	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.62e-05	0.000201	CbGpPWpGaD
Ergotamine—HTR2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.62e-05	0.000201	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.61e-05	0.0002	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.59e-05	0.000197	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.53e-05	0.00019	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.52e-05	0.000189	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.51e-05	0.000187	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.5e-05	0.000186	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.5e-05	0.000186	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.48e-05	0.000183	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.47e-05	0.000183	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.47e-05	0.000183	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.45e-05	0.000179	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.44e-05	0.000179	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.37e-05	0.00017	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.35e-05	0.000167	CbGpPWpGaD
Ergotamine—HTR1D—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.34e-05	0.000167	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.34e-05	0.000166	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.32e-05	0.000164	CbGpPWpGaD
Ergotamine—HTR1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.31e-05	0.000163	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.24e-05	0.000154	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.24e-05	0.000154	CbGpPWpGaD
Ergotamine—HTR2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.24e-05	0.000153	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.17e-05	0.000145	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—ALB—acquired immunodeficiency syndrome	1.17e-05	0.000145	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.16e-05	0.000143	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.15e-05	0.000143	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.04e-05	0.000129	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.04e-05	0.000129	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.01e-05	0.000125	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1e-05	0.000124	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1e-05	0.000124	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.97e-06	0.000124	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.59e-06	0.000119	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.54e-06	0.000118	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.84e-06	0.00011	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.8e-06	0.000109	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.7e-06	0.000108	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.65e-06	0.000107	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.52e-06	0.000106	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.47e-06	0.000105	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	8.07e-06	0.0001	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.93e-06	9.84e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.91e-06	9.82e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.87e-06	9.77e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.77e-06	9.64e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.3e-06	9.05e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.79e-06	8.42e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	6.44e-06	7.99e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.13e-06	7.6e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.92e-06	7.34e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.89e-06	7.3e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.64e-06	6.99e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.2e-06	6.45e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.11e-06	6.34e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.01e-06	6.21e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	4.97e-06	6.17e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.65e-06	5.77e-05	CbGpPWpGaD
